The trading price of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) closed higher on Monday, Feb 22, closing at $21.2, 8.63% higher than its previous close.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Traders who pay close attention to intraday price movement should know that it fluctuated between $19.51 and $25.00. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 0.66. In examining the 52-week price action we see that the stock hit a 52-week high of $25.48 and a 52-week low of $0.7. Over the past month, the stock has gained 27.66% in value.

Aclaris Therapeutics, Inc., whose market valuation is $1.19 Billion at the time of this writing, is expected to release its quarterly earnings report in Apr 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.27 per share this quarter, however they have predicted annual earnings per share of -$1.16 for 2021 and -$0.97 for 2022. It means analysts are expecting annual earnings per share growth of -0.7% this year and -0.16% next year.

Analysts have forecast the company to bring in revenue of $1.39 Million for the quarter, with the likely lows of $1.18 Million and highs of $1.6 Million. The average estimate suggests sales will likely up by 26.9% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $6.29 Million. The company’s revenue is forecast to grow by +48.8% over what it did in 2020.

On the technical side, indicators suggest ACRS has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.

To see how Aclaris Therapeutics, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: ACRS stock’s performance was +8.63% in the latest trading, and +1488.28% in the past year, while Zoetis Inc Cl A (ZTS) has traded +0.1% on the day and positioned +12.61% higher than it was a year ago. Another comparable company Takeda Pharmaceutical CO Ltd (TAK) saw its stock close -1.81% lower in the most recent trading session but was down -7.66% in a year. Furthermore, Catalent Inc (CTLT) showed an increase of 8.63% on the day while its price kept rising at 1488.28% over the past year. Aclaris Therapeutics, Inc. has a P/E ratio of 0, compared to Zoetis Inc Cl A’s 46.79 and Takeda Pharmaceutical CO Ltd’s 21.38. Also in last trading session, the S&P 500 Index has soared -0.77%, while the Dow Jones Industrial also saw a positive session, up +0.09% on the day.

An evaluation of the daily trading volume of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) indicates that the 3-month average is 3.15 Million. However, this figure has increased over the past 10 days to an average of 606.95 Million.

The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Currently, records show that 50.51 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 9.64% of outstanding shares, whereas institutions hold 66.13%. The stats also highlight that short interest as of January 28, 2021, stood at 949.62 Million shares, resulting in a short ratio of 0.14 at that time. From this, we can conclude that short interest is 1.88% of the company’s total outstanding shares. It is noteworthy that short shares in January were up slightly from the previous month’s figure, which was 688.19 Million. However, since the stock’s price has seen +255.95% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free


Please enter your comment!
Please enter your name here